| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1995;91:521-531.)
© 1995 American Heart Association, Inc.
Articles |
From the American Heart AssociationBugher Foundation Center for Molecular Biology of the Cardiovascular System, Stanford University School of Medicine, Stanford, Calif.
Correspondence to Victor J. Dzau, MD, Falk Cardiovascular Research Center, Stanford University School of Medicine, 300 Pasteur Dr, Stanford, CA 94305-5246.
Abstract The use of genetic models has greatly assisted investigations of the natural history, mechanisms, and potential therapy for human vascular disease. In the past, genetic models of vascular disease were obtained through serendipity and/or selective breeding to obtain inbred lines that express the phenotype of interest. This approach has yielded several valuable models of atherosclerosis and hypertension. In the past several years, the advent of molecular techniques has enabled investigators to produce additional novel genetic models of disease that have further enhanced the study of vascular biology and medicine. Transgenic techniques and the techniques of homologous recombination have allowed researchers to alter the genotype of an animal in a precise manner and to study the resultant change in phenotype. More recently, techniques of in vivo gene transfer have also accelerated and enhanced the development of novel models. The application of these methodologies has resulted in important breakthroughs in our understanding of the pathogenesis and treatment of vascular diseases. In this review, we compare and contrast these technologies along with examples of their use in the studies of vascular biology and medicine.
Key Words: hypertension atherosclerosis genes recombination mapping
This article has been cited by other articles:
![]() |
B. Hocher and M. Paul Transgenic animal models for the analysis of the renal endothelin system Nephrol. Dial. Transplant., July 1, 2000; 15(7): 935 - 937. [Full Text] [PDF] |
||||
![]() |
S. A Doggrell and L. Brown Rat models of hypertension, cardiac hypertrophy and failure Cardiovasc Res, July 1, 1998; 39(1): 89 - 105. [Full Text] [PDF] |
||||
![]() |
A. M Shah, S. J Sollott, and E. G Lakatta Physio-pharmacological evaluation of myocardial performance: an integrative approach Cardiovasc Res, July 1, 1998; 39(1): 148 - 154. [Full Text] [PDF] |
||||
![]() |
N. Sato, T. Katsuya, H. Rakugi, S. Takami, Y. Nakata, T. Miki, J. Higaki, and T. Ogihara Association of Variants in Critical Core Promoter Element of Angiotensinogen Gene With Increased Risk of Essential Hypertension in Japanese Hypertension, September 1, 1997; 30(3): 321 - 325. [Abstract] [Full Text] |
||||
![]() |
S.-i. Takeda, Y. Sawa, M. Minami, Y. Kaneda, Y. Fujii, R. Shirakura, M. Yanagisawa, and H. Matsuda Experimental Bronchiolitis Obliterans Induced by In Vivo HVJ-Liposome-Mediated Endothelin-1 Gene Transfer Ann. Thorac. Surg., June 1, 1997; 63(6): 1562 - 1567. [Abstract] [Full Text] |
||||
![]() |
P. Wiesel, L. Mazzolai, J. Nussberger, and T. Pedrazzini Two-Kidney, One Clip and One-Kidney, One Clip Hypertension in Mice Hypertension, April 1, 1997; 29(4): 1025 - 1030. [Abstract] [Full Text] |
||||
![]() |
V. J. Dzau and M. Horiuchi In Vivo Gene Transfer and Gene Modulation in Hypertension Research Hypertension, December 1, 1996; 28(6): 1132 - 1137. [Abstract] [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |